Bio-Thera Kicks Off Phase III Trial For Stelara Rival

Chinese Biosimilars Developer Begins Study For BAT2206 Ustekinumab Candidate

Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.

Clinical Trial
Bio-Thera has begun Phase III trials for ustekinumab • Source: Shutterstock

China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2206 proposed biosimilar version of Stelara (ustekinumab), the blockbuster treatment for Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis marketed by Johnson & Johnson’s Janssen.

“The first patient has been dosed in a Phase III clinical study for BAT2206,” Bio-Thera announced, describing the trial as...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.